Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vivoryon Therapeutics N.V., a clinical stage biotechnology company, has announced the successful completion of its share capital reduction from EUR 1.00 to EUR 0.01 per share, a move aimed at enhancing the company’s financial agility. This strategic step, approved by shareholders and unopposed in the creditor opposition procedure, is expected to facilitate new financing, M&A activities, and the granting of equity awards. The reduction amount has been transferred to the company’s distributable reserves, with no change in the total number of shares issued.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.